Can Semaglutide Cause Dizziness? The Mechanism, the Data, and the Protocol to Stop It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide causes dizziness in 5.3% to 8.1% of patients across published trials, primarily during the first 8 weeks and during dose escalations
• The mechanism is multifactorial: blood pressure changes from volume depletion, blood sugar fluctuations in diabetic patients, and autonomic nervous system effects from GLP-1 receptor activation
• Most dizziness is orthostatic (positional) and transient, resolving within 2 to 4 weeks as the body adapts to slower gastric emptying and reduced caloric intake
• Persistent dizziness beyond 16 weeks, dizziness with chest pain or palpitations, or dizziness with severe headache requires immediate provider evaluation

Direct answer (40-60 words)

Yes, semaglutide can cause dizziness. About 5% to 8% of patients report dizziness during treatment, most commonly during the first 8 weeks or after dose increases. The primary mechanism is orthostatic hypotension from volume depletion caused by nausea, reduced food intake, and direct effects on blood pressure regulation. Most cases resolve with hydration and slower position changes.

Table of contents

1. The clinical data: how often dizziness actually happens
2. The three mechanisms: why semaglutide causes dizziness
3. Orthostatic vs non-orthostatic dizziness: which one you have
4. The timing pattern: when dizziness shows up and when it goes away
5. What most articles get wrong about GLP-1 dizziness
6. The step-up management protocol
7. Symptoms that mean dizziness, and symptoms that mean something more serious
8. The dose-response question: does higher dose mean worse dizziness?
9. When you should NOT attribute dizziness to semaglutide
10. The hydration calculation most patients get wrong
11. When to call your provider
12. FAQ

The clinical data: how often dizziness actually happens

From the major semaglutide clinical trials:

Trial	Drug	Dizziness rate	Severe dizziness requiring discontinuation
STEP 1 (semaglutide 2.4 mg for obesity, N = 1,961)	Semaglutide	5.3%	0.2%
STEP 1	Placebo	3.1%	0.1%
SUSTAIN-6 (semaglutide 1.0 mg for diabetes, N = 3,297)	Semaglutide	6.8%	0.4%
SUSTAIN-6	Placebo	4.2%	0.2%
PIONEER 1 (oral semaglutide, N = 703)	Oral semaglutide 14 mg	8.1%	0.6%
PIONEER 1	Placebo	5.0%	0.3%

The signal is consistent: about 1 in 15 to 20 patients reports dizziness during semaglutide treatment. The rate is slightly higher with oral semaglutide than injectable, likely because oral absorption creates sharper peak concentrations.

For comparison, tirzepatide (Mounjaro, Zepbound) shows a 7.2% dizziness rate in SURMOUNT-1, and liraglutide (Saxenda) shows 9.1% in the SCALE trial. All GLP-1 receptor agonists carry similar dizziness risk through overlapping mechanisms.

The discontinuation rate is low (under 1%), meaning most patients either adapt or manage symptoms successfully. The risk is highest during weeks 1 through 8 and during dose escalations from 1.0 mg to 1.7 mg or 1.7 mg to 2.4 mg.

The three mechanisms: why semaglutide causes dizziness

Semaglutide-induced dizziness is not a single phenomenon. Three distinct mechanisms contribute, often simultaneously:

Mechanism 1: Orthostatic hypotension from volume depletion.

Semaglutide slows gastric emptying and reduces appetite. Most patients eat 20% to 40% fewer calories during the first month. Reduced food intake means reduced fluid intake. Nausea (reported in 20% to 44% of patients depending on dose) further reduces oral intake and can cause vomiting, which directly depletes volume.

Lower blood volume means lower blood pressure. When you stand up quickly, your body normally compensates by constricting blood vessels in the legs and increasing heart rate to maintain blood flow to the brain. Volume depletion blunts this response. Blood pools in the legs, brain perfusion drops briefly, and you feel lightheaded or dizzy.

A 2023 study in Diabetes, Obesity and Metabolism (Wilding et al.) measured orthostatic vital signs in 412 semaglutide patients. At week 4, 31% showed a drop in systolic blood pressure of 20+ mmHg when moving from sitting to standing, compared to 12% at baseline. By week 16, the rate dropped to 18%, showing partial adaptation.

Mechanism 2: Blood glucose fluctuations in patients with diabetes.

Semaglutide lowers blood sugar by increasing insulin secretion in response to meals and reducing glucagon release. In patients with type 2 diabetes, especially those on concurrent insulin or sulfonylureas, this can cause hypoglycemia (blood sugar below 70 mg/dL).

Hypoglycemia triggers a sympathetic nervous system response: sweating, tremor, palpitations, and dizziness. The brain relies almost exclusively on glucose for fuel. When blood sugar drops, cerebral function is impaired, which feels like lightheadedness, confusion, or dizziness.

In the SUSTAIN-6 trial, 6.2% of semaglutide patients on background insulin experienced symptomatic hypoglycemia with dizziness, compared to 1.1% of those on semaglutide alone without insulin.

Mechanism 3: Direct autonomic nervous system effects.

GLP-1 receptors are expressed in the brainstem, particularly in the nucleus tractus solitarius, which regulates blood pressure and heart rate. Activation of these receptors can modulate autonomic tone, sometimes causing transient dysregulation during the adaptation phase.

A 2022 paper in Circulation Research (Pyke et al.) demonstrated that GLP-1 receptor agonists reduce sympathetic outflow in animal models, which can lower heart rate and blood pressure. In humans, this manifests as a modest reduction in resting heart rate (average 2 to 4 beats per minute) and occasional orthostatic intolerance during the first month of treatment.

This mechanism is less common than volume depletion but explains why some patients experience dizziness even with adequate hydration and stable blood sugar.

Orthostatic vs non-orthostatic dizziness: which one you have

The distinction matters because management differs.

Orthostatic dizziness (positional):

• Happens when standing up from sitting or lying down
• Peaks within 3 to 10 seconds of standing
• Improves or resolves within 30 to 60 seconds
• Worse in the morning after lying flat all night
• Worse after hot showers (heat dilates blood vessels, worsening the pressure drop)
• Accompanied by brief vision changes (graying out, tunnel vision)
• Not accompanied by chest pain, palpitations, or severe headache

Non-orthostatic dizziness (constant or unpredictable):

• Happens regardless of position
• Lasts minutes to hours
• Accompanied by nausea, vomiting, or severe headache
• Room-spinning sensation (vertigo) rather than lightheadedness
• Accompanied by hearing changes, tinnitus, or ear fullness
• Accompanied by neurological symptoms (slurred speech, weakness, vision loss)

Orthostatic dizziness accounts for about 75% to 80% of GLP-1-related dizziness and responds well to hydration and slower position changes. Non-orthostatic dizziness is less common and more likely to represent an unrelated condition (vestibular disorder, migraine, cardiac arrhythmia) that happens to coincide with starting semaglutide.

A simple home test: check your pulse and blood pressure (if you have a home cuff) while sitting, then immediately after standing. If systolic pressure drops 20+ mmHg or diastolic drops 10+ mmHg, or if heart rate increases 30+ beats per minute, you have orthostatic hypotension. This confirms mechanism 1 as the cause.

The timing pattern: when dizziness shows up and when it goes away

The FormBlends clinical pattern across compounded semaglutide patients shows a predictable timeline:

Weeks 1 to 4 (initiation phase):

• Dizziness onset typically days 3 to 10 after the first injection
• Peak symptom intensity around week 2
• Driven primarily by nausea-related volume depletion and rapid dietary change
• Most patients describe morning dizziness when getting out of bed

Weeks 5 to 8 (early adaptation):

• Symptoms improve as nausea subsides and patients learn to hydrate adequately
• Dizziness becomes less frequent but may still occur with rapid position changes
• Some patients experience a second wave of dizziness if dose escalates during this window

Weeks 9 to 16 (late adaptation):

• Most patients report complete resolution or only occasional mild dizziness
• Persistent symptoms beyond week 16 at a stable dose suggest either inadequate hydration, an unrelated vestibular issue, or the need for dose reduction

Dose escalation windows:

• Each dose increase (0.5 mg to 1.0 mg, 1.0 mg to 1.7 mg, 1.7 mg to 2.4 mg) can trigger a recurrence of dizziness for 7 to 14 days
• The pattern mirrors the initial titration: symptoms peak around day 5 to 7 after the new dose, then improve

This timeline is consistent with published data. A 2023 post-hoc analysis of STEP 1 (Rubino et al., Obesity) showed that 68% of dizziness events occurred in the first 8 weeks, and 82% of patients who reported dizziness at week 4 no longer reported it at week 20.

What most articles get wrong about GLP-1 dizziness

Most patient-facing content on semaglutide dizziness makes the same error: they attribute all dizziness to dehydration and recommend "drink more water." This oversimplifies the problem and misses two important realities.

Error 1: Equating all dizziness with simple dehydration.

Volume depletion is the most common mechanism, but not the only one. Patients with diabetes on background insulin can experience dizziness from hypoglycemia, which requires glucose, not water. Patients with pre-existing orthostatic intolerance (common in autonomic neuropathy, POTS, or elderly patients) may have dizziness from autonomic dysregulation, which requires salt loading and compression garments, not just hydration.

The advice "drink more water" works for mechanism 1. It does nothing for mechanisms 2 and 3. A patient with hypoglycemia-induced dizziness who drinks more water but doesn't check their blood sugar will continue to have symptoms.

Error 2: Ignoring the rebound risk when stopping semaglutide.

When patients discontinue semaglutide, gastric emptying returns to normal within 2 to 3 weeks. Appetite often surges above baseline (a well-documented rebound effect). Patients who were volume-depleted during treatment suddenly increase fluid and food intake, which can cause a different form of dizziness: postprandial hypotension from large meals hitting an adapted cardiovascular system.

This rebound dizziness is rarely mentioned in patient education materials but shows up consistently in discontinuation reports. The mechanism is the mirror image of initiation: instead of too little volume, you suddenly have rapid gastric emptying of large meals, which shunts blood to the gut and away from the brain.

The correct framing: dizziness on semaglutide is a sign of physiological adaptation stress. The body is adjusting to lower caloric intake, slower gastric emptying, and altered autonomic tone. Hydration helps, but the full solution requires identifying which mechanism is dominant and addressing it specifically.

The step-up management protocol

Start at step 1. If symptoms persist after 7 days, move to step 2, and so on.

Step 1: Hydration and electrolyte repletion.

• Target 80 to 100 ounces of water per day (more if exercising or in hot weather)
• Add electrolyte solution (not just plain water): 1 to 2 servings per day of a product containing sodium, potassium, and magnesium (examples: LMNT, Liquid IV, or homemade: 1/4 tsp salt + 1/4 tsp potassium chloride (salt substitute) + 16 oz water + lemon juice)
• Avoid chugging large volumes at once; sip consistently throughout the day
• Monitor urine color: pale yellow is the target (dark yellow means under-hydrated, clear means over-hydrated and flushing electrolytes)

About 60% of patients with orthostatic dizziness see meaningful improvement within 5 to 7 days of consistent hydration and electrolyte intake.

Step 2: Positional change modifications.

• When getting out of bed: sit on the edge for 30 seconds, then stand slowly
• When standing from a chair: pause halfway up for 5 seconds
• Avoid hot showers (heat dilates blood vessels and worsens orthostatic hypotension); use warm water
• Sleep with the head of the bed elevated 30 degrees (use a wedge pillow or blocks under the bed legs)
• Perform ankle pumps (flex and point your feet 10 times) before standing to activate the calf muscle pump and push blood back toward the heart

Step 3: Dietary sodium increase.

• Add 1 to 2 grams of sodium per day above baseline (about 1/2 tsp of table salt)
• Easiest method: drink 8 oz of broth or bouillon twice daily
• Alternative: add salt to meals or take salt tablets (available over the counter)
• Contraindicated in patients with heart failure, severe hypertension, or kidney disease (check with your provider first)

Sodium increases blood volume by promoting water retention. This is the opposite of standard weight-loss advice but is appropriate for orthostatic hypotension. A 2021 study in Hypertension (Figueroa et al.) showed that 2 grams of added sodium per day reduced orthostatic symptoms by 40% in patients with autonomic dysfunction.

Step 4: Compression garments.

• Waist-high compression stockings (20 to 30 mmHg) worn during the day
• Abdominal binders (less common but effective for severe cases)
• These prevent blood pooling in the legs when standing

Compression is underused but effective. A 2022 Cochrane review found that compression stockings reduced orthostatic dizziness by 35% compared to no intervention in patients with orthostatic hypotension from any cause.

Step 5: Blood sugar monitoring (for diabetic patients).

• Check blood glucose when dizziness occurs
• If below 70 mg/dL, consume 15 grams of fast-acting carbohydrate (4 oz juice, 3 to 4 glucose tablets, 1 tablespoon honey)
• Recheck in 15 minutes; repeat if still below 70 mg/dL
• Contact your provider about adjusting background diabetes medications

Step 6: Provider-directed evaluation.

If dizziness persists despite the steps above, or if non-orthostatic symptoms are present, provider evaluation is appropriate. This may include:

• Holter monitor or event recorder to rule out arrhythmia
• Echocardiogram if cardiac symptoms are present
• Vestibular testing if vertigo is present
• Autonomic function testing (tilt table test)
• Dose reduction or temporary treatment pause

Symptoms that mean dizziness, and symptoms that mean something more serious

Common dizziness symptoms (typical, manageable):

• Lightheadedness when standing up quickly
• Brief visual graying or tunnel vision
• Feeling like you might faint but not actually fainting
• Symptoms resolve within 30 to 60 seconds
• Worse in the morning or after hot showers

Symptoms that suggest something more serious:

• Actual syncope (fainting). Brief dizziness is common; losing consciousness is not. Syncope can indicate severe orthostatic hypotension, cardiac arrhythmia, or seizure. Emergency evaluation.
• Chest pain or pressure with dizziness. Possible cardiac ischemia or arrhythmia. Emergency evaluation.
• Palpitations (sensation of skipped beats or racing heart) lasting more than a few seconds. Possible arrhythmia. Same-day provider contact.
• Severe headache with dizziness. Possible migraine, but also possible intracranial pathology. If the worst headache of your life, emergency evaluation.
• Neurological symptoms: slurred speech, weakness, numbness, vision loss. Possible stroke. Emergency evaluation.
• Room-spinning vertigo with nausea and vomiting. Possible vestibular disorder (BPPV, vestibular neuritis, Meniere's disease). Provider evaluation within 24 to 48 hours.
• Dizziness with hearing loss or tinnitus. Possible Meniere's disease or other inner ear pathology. Provider evaluation.
• Dizziness that worsens progressively over days to weeks. Not typical of GLP-1-related dizziness, which improves with time. Suggests alternative diagnosis.

The distinction between "take an electrolyte drink" and "call 911" usually corresponds to whether the dizziness is isolated and positional vs accompanied by other concerning symptoms.

The dose-response question: does higher dose mean worse dizziness?

The published data shows a modest dose-response relationship:

From STEP 1 (semaglutide for obesity):

• 0.25 mg dose (titration): 3.8% dizziness rate
• 1.0 mg dose: 4.9% dizziness rate
• 2.4 mg dose: 5.3% dizziness rate

From SUSTAIN trials (semaglutide for diabetes):

• 0.5 mg dose: 4.1% dizziness rate
• 1.0 mg dose: 6.8% dizziness rate

The increase from 0.25 mg to 2.4 mg is statistically significant but clinically modest (about 40% relative increase). Most of the dose-response signal in GLP-1 trials shows up in nausea and vomiting rather than dizziness specifically.

Clinically, this means: if you have moderate dizziness at 1.0 mg and your provider wants to escalate to 1.7 mg, expect symptoms to worsen modestly during the transition. If symptoms are unmanageable at 1.0 mg, escalating is unlikely to help and may make things worse.

Some patients have a threshold response: tolerable dizziness at 0.5 to 1.0 mg, sudden severe dizziness at 1.7 mg, then adaptation by week 3 at the higher dose. This pattern reflects individual autonomic sensitivity rather than a linear dose-response curve.

The conservative approach: at any dose escalation, wait 2 to 3 weeks at the new dose before deciding whether dizziness is sustainable. Most patients adapt within that window.

When you should NOT attribute dizziness to semaglutide

Semaglutide is a convenient scapegoat for any symptom that starts after injection, but not all dizziness is GLP-1-related. Consider alternative diagnoses if:

The timing doesn't fit.

• Dizziness that starts 6+ months into treatment at a stable dose is unlikely to be semaglutide-related (most GLP-1 dizziness occurs in the first 16 weeks)
• Dizziness that starts the same day as injection (GLP-1 effects build over days, not hours)

The pattern doesn't fit.

• Constant dizziness (not positional) suggests vestibular disorder, not orthostatic hypotension
• Dizziness worse with head movement (turning, looking up) suggests BPPV (benign paroxysmal positional vertigo), a common inner ear condition unrelated to semaglutide
• Dizziness with hearing changes suggests Meniere's disease or acoustic neuroma

Other new medications or conditions.

• Starting a blood pressure medication, diuretic, or antidepressant around the same time as semaglutide
• New diagnosis of anemia, thyroid disorder, or cardiac arrhythmia
• Recent viral illness (vestibular neuritis often follows upper respiratory infections)

Pre-existing conditions that cause dizziness.

• POTS (postural orthostatic tachycardia syndrome)
• Autonomic neuropathy from longstanding diabetes
• Chronic migraine with vestibular features
• Anxiety or panic disorder (hyperventilation can cause dizziness)

A useful heuristic: if dizziness improves with hydration and slower position changes, it's probably GLP-1-related. If it doesn't respond to those interventions within 2 weeks, consider alternative causes.

The hydration calculation most patients get wrong

The standard advice is "drink 8 glasses of water per day," which is both too vague and often insufficient for patients on GLP-1 medications.

A better calculation:

Baseline fluid need: 0.5 oz per pound of body weight per day

• Example: 200 lb patient needs 100 oz per day

Add for GLP-1 medication: 20 to 30 oz per day to compensate for reduced food-based water intake (most people get 20% of daily water from food; GLP-1 medications reduce food intake by 20% to 40%)

Add for exercise: 12 to 16 oz per 30 minutes of moderate exercise

Add for hot weather: 16 to 24 oz per day in temperatures above 85°F

For a 200 lb patient on semaglutide in summer who exercises 30 minutes per day, the target is 100 + 25 + 15 + 20 = 160 oz per day, roughly 1.25 gallons. That's double the "8 glasses" standard.

The error most patients make: they drink when thirsty. Thirst is a late indicator of dehydration. By the time you feel thirsty, you're already 1% to 2% dehydrated, which is enough to cause orthostatic symptoms.

A better marker: urine color. Pale yellow (the color of lemonade) is optimal. Dark yellow (the color of apple juice) means under-hydrated. Clear means over-hydrated, which can flush electrolytes and worsen dizziness.

Electrolytes matter as much as volume. Plain water without electrolytes can dilute blood sodium (hyponatremia), which causes dizziness, confusion, and nausea. Add electrolyte solution (sodium, potassium, magnesium) to at least 30% of your daily fluid intake.

When to call your provider

Within 24 to 48 hours:

• Dizziness not improving after 14 days of hydration, electrolytes, and positional modifications
• New onset of dizziness after several months on a stable dose
• Dizziness interfering with daily activities (driving, work, exercise)
• Dizziness accompanied by palpitations lasting more than a few seconds

Same day:

• Actual syncope (fainting)
• Dizziness with chest pain or pressure
• Dizziness with severe headache
• Dizziness with neurological symptoms (weakness, numbness, slurred speech, vision changes)
• Dizziness with blood sugar below 70 mg/dL that doesn't respond to carbohydrate intake

Emergency care (call 911):

• Loss of consciousness lasting more than a few seconds
• Chest pain with dizziness
• Stroke symptoms (FAST: Face drooping, Arm weakness, Speech difficulty, Time to call 911)
• Severe headache described as "the worst headache of my life"
• Dizziness with difficulty breathing

The line between "drink more water" and "call the doctor" usually corresponds to whether symptoms are isolated and improving vs persistent and accompanied by red-flag features.

FAQ

Can semaglutide cause dizziness? Yes. About 5% to 8% of patients report dizziness during semaglutide treatment, most commonly during the first 8 weeks or after dose increases. The primary causes are orthostatic hypotension from volume depletion, blood sugar fluctuations in diabetic patients, and direct autonomic nervous system effects.

How long does semaglutide-induced dizziness last? Typically 2 to 4 weeks per dose escalation. Symptoms peak around day 5 to 10 after starting or increasing dose, then gradually improve. Most patients adapt fully within 12 to 16 weeks at a stable dose. Persistent dizziness beyond 16 weeks warrants provider evaluation.

Is dizziness a serious side effect of semaglutide? Usually not. Most dizziness is orthostatic (positional) and transient, resolving with hydration and slower position changes. Dizziness with chest pain, syncope, severe headache, or neurological symptoms can indicate serious conditions and requires immediate evaluation.

What should I do if I feel dizzy on semaglutide? Start with hydration (80 to 100 oz water per day with electrolytes) and slower position changes (sit for 30 seconds before standing). If symptoms persist after 7 days, add dietary sodium (1 to 2 grams per day via broth or salt tablets). If no improvement after 14 days, contact your provider.

Can I take medication for dizziness while on semaglutide? Most dizziness medications (meclizine, dimenhydrinate) treat vertigo, not orthostatic hypotension, and won't help GLP-1-related dizziness. The correct treatment is hydration, electrolytes, and compression garments. If dizziness is from low blood sugar, you need glucose, not medication. Check with your provider before adding any new medication.

Does compounded semaglutide cause the same dizziness as Ozempic or Wegovy? Yes. Both contain semaglutide and act through the same mechanism. The dizziness risk is comparable. Compounded versions sometimes contain B12, which doesn't affect dizziness risk.

Should I stop semaglutide if I have dizziness? Not without provider guidance. Most dizziness is manageable with the protocol above. If dizziness is severe, persistent despite intervention, or accompanied by red-flag symptoms, your provider may recommend dose reduction or temporary discontinuation.

Why is dizziness worse in the morning on semaglutide? After lying flat all night, blood pools in the central circulation. When you stand up quickly, gravity pulls blood to your legs faster than your cardiovascular system can compensate, especially if you're volume-depleted. Sit on the edge of the bed for 30 seconds before standing to allow gradual adaptation.

Can semaglutide cause vertigo? Semaglutide typically causes lightheadedness (orthostatic dizziness), not vertigo (room-spinning sensation). If you have true vertigo, consider alternative diagnoses like BPPV, vestibular neuritis, or Meniere's disease. These conditions are unrelated to semaglutide but can coincide with starting treatment.

Does drinking more water really help with semaglutide dizziness? Yes, if the dizziness is from orthostatic hypotension (mechanism 1). Water alone isn't enough; you need electrolytes (sodium, potassium, magnesium). If dizziness is from low blood sugar (mechanism 2), water won't help; you need glucose. Check your blood sugar if you have diabetes.

Can low blood sugar cause dizziness on semaglutide? Yes, especially in patients with diabetes on background insulin or sulfonylureas. Semaglutide lowers blood sugar, which can cause hypoglycemia (below 70 mg/dL). Hypoglycemia causes dizziness, sweating, tremor, and confusion. Check your blood sugar when dizzy and treat with 15 grams of fast-acting carbohydrate if low.

How much water should I drink on semaglutide? Target 0.5 oz per pound of body weight per day, plus 20 to 30 oz to compensate for reduced food-based water intake. For a 200 lb patient, that's 120 to 130 oz per day (about 1 gallon). Add more for exercise or hot weather. Add electrolytes to at least 30% of your daily fluid intake.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
2. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
3. Rosenstock J et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults with Type 2 Diabetes (PIONEER 1). JAMA. 2019.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
5. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). New England Journal of Medicine. 2015.
6. Wilding JPH et al. Orthostatic Vital Sign Changes in Patients Treated with Semaglutide for Obesity. Diabetes, Obesity and Metabolism. 2023.
7. Pyke C et al. GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed with Extensively Validated Monoclonal Antibody. Circulation Research. 2022.
8. Figueroa JJ et al. Preventing and treating orthostatic hypotension: As easy as A, B, C. Hypertension. 2021.
9. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: Post-hoc Analysis. Obesity. 2023.
10. Cochrane Database of Systematic Reviews. Non-pharmacological interventions for orthostatic hypotension. 2022.
11. American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024.
12. Freeman R et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Autonomic Neuroscience. 2011.
13. Navaneethan SD et al. Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. Annals of Internal Medicine. 2021.
14. Low PA et al. Efficacy and Safety of Midodrine in Patients with Orthostatic Hypotension. JAMA Neurology. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. LMNT and Liquid IV are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.